tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Danielle Brill, 185 are a BUY (82.22%), 35 are a HOLD (15.56%), 5 are a SELL (2.22%).
Analyst Danielle Brill, currently employed at TRUIST, carries an average stock price target met ratio of 52.62% that have a potential upside of 35.77% achieved within 195 days. Previously, Danielle Brill worked at RAYMOND JAMES.
Danielle Brill’s has documented 426 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 17-Feb-2026.
Analyst best performing recommendations are on AGIO (AGIOS PHARM).
The best stock recommendation documented was for AGIO (AGIOS PHARM) at 10/31/2024. The price target of $51 was fulfilled within 6 days with a profit of $6.57 (14.79%) receiving and performance score of 24.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 08-Dec-2021
$23
$-0.99 (-4.13%)
$22
18 days ago
(06-Feb-2026)
17/17 (100%)
$-0.56 (-2.38%)
84
Buy Since 26-Jun-2025
$31
$7.01 (29.22%)
$32
21 days ago
(03-Feb-2026)
0/5 (0%)
$6.24 (25.20%)
Buy Since 21-Oct-2025
$36
$12.01 (50.06%)
$33
1 months 18 days ago
(06-Jan-2026)
0/2 (0%)
$9.06 (33.63%)
Buy Since 17-Oct-2023
$40
$16.01 (66.74%)
$39
1 months 18 days ago
(06-Jan-2026)
2/7 (28.57%)
$13.06 (48.48%)
467
Hold Since 03-Nov-2022
$25
$1.01 (4.21%)
2 months 13 days ago
(11-Dec-2025)
18/21 (85.71%)
$-1.68 (-6.30%)
118
Which stock is Danielle Brill is most bullish on?
Which stock is Danielle Brill is most reserved on?
What Year was the first public recommendation made by Danielle Brill?
